Intellia Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
8.31
0.13
(1.59%)
Volume:
1,946,473
52 week range:
5.90 - 28.18
Market Cap:
860.230M
Company Description:
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.